Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 185 articles:
HTML format
Text format



Single Articles


    June 2018
  1. FARAH M, Nagarajan P, Curry JL, Tang Z, et al
    Spitzoid melanoma with histopathologic features of ALK gene rearrangement exhibiting ALK copy number gain: A novel mechanism of ALK activation in spitzoid neoplasia.
    Br J Dermatol. 2018 Jun 13. doi: 10.1111/bjd.16881.
    PubMed     Text format     Abstract available


  2. HALVORSEN JA, Loberg M, Gjersvik P, Roscher I, et al
    Why a randomized melanoma screening trial is not a good idea.
    Br J Dermatol. 2018 Jun 12. doi: 10.1111/bjd.16784.
    PubMed     Text format    


  3. PODLIPNIK S, Moreno-Ramirez D, Carrera C, Barreiro A, et al
    Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with AJCC stage IIB, IIC and III malignant melanoma.
    Br J Dermatol. 2018 Jun 7. doi: 10.1111/bjd.16833.
    PubMed     Text format     Abstract available


  4. STENEHJEM JS, Veierod MB, Nilsen LT, Ghiasvand R, et al
    Anthropometric factors and Breslow thickness: Prospective data on 2570 cutaneous melanoma cases in the population-based Janus Cohort.
    Br J Dermatol. 2018 Jun 1. doi: 10.1111/bjd.16825.
    PubMed     Text format     Abstract available


    May 2018
  5. WAN MT, Ming ME
    Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal.
    Br J Dermatol. 2018 May 15. doi: 10.1111/bjd.16785.
    PubMed     Text format     Abstract available


  6. CAYUELA A, Cayuela L, Rodriguez-Dominguez S, Lorente AI, et al
    Is melanoma mortality declining in Spain? Analysis of trends 1975-2016.
    Br J Dermatol. 2018 May 14. doi: 10.1111/bjd.16777.
    PubMed     Text format     Abstract available


  7. FUJISAWA Y
    Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors: reply from the authors.
    Br J Dermatol. 2018 May 7. doi: 10.1111/bjd.16689.
    PubMed     Text format    


  8. KRAEMER KH, Tamura D, Khan SG
    Pembrolizumab treatment of a patient with xeroderma pigmentosum with disseminated melanoma and multiple nonmelanoma skin cancers.
    Br J Dermatol. 2018;178:1009.
    PubMed     Text format    


    April 2018
  9. RAUWERDINK DJW, Roach REJ, Etty M, Kukutsch NA, et al
    Melanoma diagnosis during periodic surveillance of patients with multiple atypical naevi.
    Br J Dermatol. 2018 Apr 28. doi: 10.1111/bjd.16708.
    PubMed     Text format     Abstract available


  10. LANGAN EA, Gratz V, Billmann F, Zillikens D, et al
    Does the gastrointestinal microbiome contribute to the "obesity paradox" in melanoma survival?
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16681.
    PubMed     Text format     Abstract available


  11. KIM J, Kim YH, Park B, Seo HM, et al
    Multispectral ex vivo photoacoustic imaging of cutaneous melanoma for better selection of the excision margin.
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16677.
    PubMed     Text format     Abstract available


  12. MACHET L, Zaragoza J, Finon A, Garnier M, et al
    Baseline neutrophil to lymphocyte ratio in patients with advanced melanoma treated with immune check point inhibitors.
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16675.
    PubMed     Text format     Abstract available


  13. HAAS L, Wiesner T, Obenauf AC
    A new era of proactive melanoma therapy: hit hard, hit early.
    Br J Dermatol. 2018;178:817-820.
    PubMed     Text format    


    March 2018
  14. VU M, Adler NR, Wee E, Wolfe R, et al
    Impact of naevus association on survival for nodular and superficial spreading melanomas.
    Br J Dermatol. 2018 Mar 24. doi: 10.1111/bjd.16556.
    PubMed     Text format     Abstract available


  15. FORSCHNER A, Keim U, Hofmann M, Spankuch I, et al
    Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: Results of a prospective multicentre clinical study in 476 pigmented lesions.
    Br J Dermatol. 2018 Mar 22. doi: 10.1111/bjd.16565.
    PubMed     Text format     Abstract available


  16. MARCHAND A, Tallet A, Collin C, Cormier B, et al
    A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
    Br J Dermatol. 2018 Mar 1. doi: 10.1111/bjd.16499.
    PubMed     Text format     Abstract available


  17. BARRAGAN-ESTUDILLO ZF, Jesus-Silva MA, Chavez-Bourgeois MM, Brito J, et al
    Image Gallery: Transition pattern in acral melanoma.
    Br J Dermatol. 2018;178:e225.
    PubMed     Text format    


    February 2018
  18. LONGO C, Lallas A, Kyrgidis A, Bassoli S, et al
    Wide skin markings pattern - melanoma descriptor or patient-related factor?: reply from authors.
    Br J Dermatol. 2018 Feb 7. doi: 10.1111/bjd.16430.
    PubMed     Text format     Abstract available


  19. RISHPON A, Marchetti M, Marghoob A
    Wide skin markings pattern - melanoma descriptor or patient-related factor?
    Br J Dermatol. 2018 Feb 6. doi: 10.1111/bjd.16420.
    PubMed     Text format     Abstract available


  20. FUJISAWA Y, Yoshino K, Otsuka A, Funakoshi T, et al
    Baseline neutrophil to lymphocyte ratio combined with serum LDH level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
    Br J Dermatol. 2018 Feb 6. doi: 10.1111/bjd.16427.
    PubMed     Text format     Abstract available


  21. DANDO EE, Lim GFS, Ho J, James A, et al
    Image Gallery: Pigmented mammary Paget disease: a rare clinicopathological variant mimicking melanoma.
    Br J Dermatol. 2018;178:e143.
    PubMed     Text format    


  22. CUST AE
    Prognostic features for acral lentiginous melanoma.
    Br J Dermatol. 2018;178:311-312.
    PubMed     Text format    


  23. BELL KJL, Cust AE
    Beyond country-specific incidence and mortality: the global burden of melanoma.
    Br J Dermatol. 2018;178:315-316.
    PubMed     Text format    


    January 2018
  24. BORSARI S, Pampena R, Benati E, Bombonato C, et al
    In vivo dermoscopic and confocal microscopy multi-step algorithm to detect in situ melanomas.
    Br J Dermatol. 2018 Jan 21. doi: 10.1111/bjd.16364.
    PubMed     Text format     Abstract available


  25. LAINO AM, Berry EG, Jagirdar K, Lee KJ, et al
    Iris pigmented lesions as a marker of cutaneous melanoma risk: an Australian case-control study.
    Br J Dermatol. 2018 Jan 8. doi: 10.1111/bjd.16323.
    PubMed     Text format     Abstract available


  26. VERYKIOU S, Edwards N, Hill D
    How breakthroughs in translational research have impacted treatment strategies for melanoma.
    Br J Dermatol. 2018;178:5-8.
    PubMed     Text format    


  27. MUTHIAH S, Tang D, Nasr B, Verykiou S, et al
    A new era in holistic care: bridging the gap between dermatologists and oncologists for the treatment of malignant melanoma.
    Br J Dermatol. 2018;178:1-4.
    PubMed     Text format    


  28. WIESNER T, Zbyszewski A
    Progress in the diagnosis and therapy of melanoma.
    Br J Dermatol. 2018;178:12-14.
    PubMed     Text format    


  29. WEHNER MR
    Sunscreen and melanoma prevention: evidence and expectations.
    Br J Dermatol. 2018;178:15-16.
    PubMed     Text format    


    December 2017
  30. MCINERNEY-LEO AM, Wheeler L, Sturm RA, Tan JM, et al
    Point mutation in p14(ARF) -specific exon 1beta of CDKN2A causing familial melanoma and astrocytoma.
    Br J Dermatol. 2017 Dec 26. doi: 10.1111/bjd.16275.
    PubMed     Text format     Abstract available


  31. DE UNAMUNO BUSTOS B, Murria Estal R, Perez Simo G, Simarro Farinos J, et al
    Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma.
    Br J Dermatol. 2017 Dec 26. doi: 10.1111/bjd.16254.
    PubMed     Text format     Abstract available


  32. SALOMON G, Maza A, Boulinguez S, Paul C, et al
    Efficacy of anti-PD-1 on skin carcinomas and melanoma metastases in an Xeroderma Pigmentosum patient.
    Br J Dermatol. 2017 Dec 23. doi: 10.1111/bjd.16270.
    PubMed     Text format     Abstract available


  33. OLSEN CM, Wilson LF, Green AC, Biswas N, et al
    How many melanomas might be prevented if more people applied sunscreen regularly?
    Br J Dermatol. 2017 Dec 14. doi: 10.1111/bjd.16079.
    PubMed     Text format     Abstract available


    November 2017
  34. WINSLOW UC, Nordestgaard BG, Afzal S
    High plasma 25-hydroxyvitamin D and high risk of non-melanoma skin cancer: a Mendelian randomisation study of 97849 individuals.
    Br J Dermatol. 2017 Nov 16. doi: 10.1111/bjd.16127.
    PubMed     Text format     Abstract available


  35. DEL PUERTO C, Navarrete-Dechent C, Molgo M, Camargo CA Jr, et al
    Immunohistochemical expression of vitamin D receptor in melanocytic nevi and cutaneous melanoma. A case-control study.
    Br J Dermatol. 2017 Nov 6. doi: 10.1111/bjd.16103.
    PubMed     Text format     Abstract available


    October 2017
  36. TRAN AD, Fogarty G, Nowak AK, Espinoza D, et al
    A systematic review and meta-analysis of utility estimates in melanoma.
    Br J Dermatol. 2017 Oct 27. doi: 10.1111/bjd.16098.
    PubMed     Text format     Abstract available


  37. SEO JW, Ha SM, Song KH
    Insulin-Like Growth Factor-II mRNA-Binding Protein 3 as a Novel Prognostic Biomarker for Acral Lentiginous Melanoma.
    Br J Dermatol. 2017 Oct 19. doi: 10.1111/bjd.16077.
    PubMed     Text format     Abstract available


  38. BASSOLI S, Kyrgidis A, Ciardo S, Casari A, et al
    Uncovering the diagnostic dermoscopic features of flat melanomas located on the lower limbs.
    Br J Dermatol. 2017 Oct 7. doi: 10.1111/bjd.16030.
    PubMed     Text format     Abstract available


  39. SCHAIDER H, Sturm RA
    The evolving universe of BRAF mutations in melanoma.
    Br J Dermatol. 2017;177:893.
    PubMed     Text format    


  40. ROBINSON JK, Spring B
    Personalized melanoma genomic risk information:perception of shared risk initiates sharing with family.
    Br J Dermatol. 2017;177:890-891.
    PubMed     Text format    


    September 2017
  41. SATTLER EC, Ertl-Wagner B, Pellegrini C, Peris K, et al
    Cutaneous melanoma in Birt-Hogg-Dube syndrome - part of the clinical spectrum?
    Br J Dermatol. 2017 Sep 4. doi: 10.1111/bjd.15937.
    PubMed     Text format     Abstract available


  42. ZNAOR A
    Melanoma burden, healthcare utilization and the potential for overdiagnosis in the elderly U.S. population.
    Br J Dermatol. 2017;177:625.
    PubMed     Text format    


    August 2017
  43. YOULDEN DR, Baade PD, Aitken JF, Green AC, et al
    Prognostic importance of a second invasive primary melanoma according to tumor stage.
    Br J Dermatol. 2017 Aug 3. doi: 10.1111/bjd.15863.
    PubMed     Text format     Abstract available


  44. BERK-KRAUSS J, Stein JA
    The role of access to care in acral lentiginous melanoma survival.
    Br J Dermatol. 2017;177:341-342.
    PubMed     Text format    


  45. HILL D, Lovat P
    Cover Image: Invasion of a cutaneous melanoma tumour.
    Br J Dermatol. 2017;177:599.
    PubMed     Text format    


    July 2017
  46. ADLER NR, Kelly JW, Haydon A, McLean CA, et al
    Clinicopathological characteristics and prognosis of patients with multiple primary melanomas.
    Br J Dermatol. 2017 Jul 28. doi: 10.1111/bjd.15855.
    PubMed     Text format     Abstract available


  47. DIAS-SANTAGATA D, Selim MA, Su Y, Peng Y, et al
    KIT Mutations and CD117 Overexpression Are Markers of Better Progression-Free Survival in Vulvar Melanomas.
    Br J Dermatol. 2017 Jul 22. doi: 10.1111/bjd.15836.
    PubMed     Text format     Abstract available


  48. TERAMOTO Y, Keim U, Gesierich A, Schuler G, et al
    Acral lentiginous melanoma - a skin cancer with unfavourable prognostic features. A study of the German Central Malignant Melanoma Registry (CMMR) in 2050 patients.
    Br J Dermatol. 2017 Jul 14. doi: 10.1111/bjd.15803.
    PubMed     Text format     Abstract available


  49. GIBBS DC, Ward SV, Orlow I, Cadby G, et al
    Functional melanoma-risk variant IRF4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas.
    Br J Dermatol. 2017 Jul 1. doi: 10.1111/bjd.15784.
    PubMed     Text format     Abstract available


  50. MAHER NG, Guitera P
    Imiquimod treatment for lentigo maligna: LIMIT-1 trial.
    Br J Dermatol. 2017;177:324-325.
    PubMed     Text format    


    June 2017
  51. SMIT AK, Keogh LA, Newson AJ, Butow PN, et al
    Does personalised melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?
    Br J Dermatol. 2017 Jun 19. doi: 10.1111/bjd.15744.
    PubMed     Text format     Abstract available


  52. KIM SK, Barker CA
    Outcomes of radiation therapy for advanced T3/T4 non-melanoma cutaneous squamous cell and basal cell carcinoma.
    Br J Dermatol. 2017 Jun 15. doi: 10.1111/bjd.15728.
    PubMed     Text format     Abstract available


  53. CERIO R, Moir G
    Palliative electrochemotherapy treatment of metastatic malignant melanoma.
    Br J Dermatol. 2017;176:1427.
    PubMed     Text format    


  54. JONES G
    Methotrexate increases the risk of melanoma: or does it?
    Br J Dermatol. 2017;176:1429-1430.
    PubMed     Text format    


    May 2017
  55. RIBERO S, Carrera C, Tell-Marti G, Pastorino C, et al
    Amelanotic melanoma in oculocutaneous albinism: a genetic, dermoscopic and reflectance confocal microscopy study.
    Br J Dermatol. 2017 May 27. doi: 10.1111/bjd.15687.
    PubMed     Text format     Abstract available


  56. SWETTER SM
    Challenges of treating melanoma in situ, lentigo maligna type: is pathological clearance the gold standard?
    Br J Dermatol. 2017;176:1115-1116.
    PubMed     Text format    


  57. ELLIS RA
    T-type calcium channels as potential biomarkers in melanoma.
    Br J Dermatol. 2017;176:1122.
    PubMed     Text format    


  58. KRENGEL S, Reyes-Mugica M
    Melanoma risk in congenital melanocytic naevi.
    Br J Dermatol. 2017;176:1114.
    PubMed     Text format    


    April 2017
  59. DIXON A, Steinman H, Anderson S, Nirenberg A, et al
    Routine usage of sentinel node biopsy in melanoma management must cease: reply from authors.
    Br J Dermatol. 2017 Apr 29. doi: 10.1111/bjd.15626.
    PubMed     Text format     Abstract available


  60. SALEH DB
    RE: Routine usage of sentinel node biopsy in melanoma management must cease.
    Br J Dermatol. 2017 Apr 29. doi: 10.1111/bjd.15619.
    PubMed     Text format     Abstract available


  61. ASGARI MM, Shen L, Sokil MM, Yeh I, et al
    Prognostics factors and survival in acral lentiginous melanoma.
    Br J Dermatol. 2017 Apr 22. doi: 10.1111/bjd.15600.
    PubMed     Text format     Abstract available


  62. GUALANO MR, Osella-Abate S, Scaioli G, Marra E, et al
    Prognostic role of Histologic regression in primary cutaneous melanoma: A Systematic Review and Meta-analysis.
    Br J Dermatol. 2017 Apr 7. doi: 10.1111/bjd.15552.
    PubMed     Text format     Abstract available


  63. NIJSTEN T, Wakkee M
    The four Ws of skin cancer surveillance in patients with melanoma: Why? Who? When? Where?
    Br J Dermatol. 2017;176:839-841.
    PubMed     Text format    


  64. MONTAUDIE H, Pradelli J, Passeron T, Lacour JP, et al
    Pulmonary sarcoid-like granulomatosis induced by nivolumab.
    Br J Dermatol. 2017;176:1060-1063.
    PubMed     Text format     Abstract available


    March 2017
  65. LOTT JP, Wang Q, Titus LJ, Onega T, et al
    Temporal Trends in Healthcare Utilization following Primary Melanoma Diagnosis among Medicare Beneficiaries.
    Br J Dermatol. 2017 Mar 30. doi: 10.1111/bjd.15530.
    PubMed     Text format     Abstract available


  66. KARIMKHANI C, Green AC, Nijsten T, Weinstock MA, et al
    The Global Burden of Melanoma: Results from Global Burden of Disease Study 2015.
    Br J Dermatol. 2017 Mar 30. doi: 10.1111/bjd.15510.
    PubMed     Text format     Abstract available


  67. KOGUCHI-YOSHIOKA H, Okiyama N, Iwamoto K, Matsumura Y, et al
    Intravenous immunoglobulin contributes to control anti-melanoma differentiation-associated protein 5 (MDA5) antibody-associated dermatomyositis with palmar violaceous macules/papules.
    Br J Dermatol. 2017 Mar 27. doi: 10.1111/bjd.15499.
    PubMed     Text format     Abstract available


  68. LICCIARDELLO M, T Giura M, Rozzo G, Marra E, et al
    Arrhythmias in metastatic melanoma patient treated with targeted therapy and ICD implant.
    Br J Dermatol. 2017 Mar 10. doi: 10.1111/bjd.15447.
    PubMed     Text format     Abstract available


  69. RICHTIG G, Hoeller C, Kashofer K, Aigelsreiter A, et al
    Beyond the BRAFV600E hotspot - Biology and clinical implications of rare BRAF gene mutations in melanoma patients.
    Br J Dermatol. 2017 Mar 9. doi: 10.1111/bjd.15436.
    PubMed     Text format     Abstract available


    February 2017
  70. CORR M, Roulston G, King N, Dornan T, et al
    Living with 'melanoma'...for a day: a phenomenological analysis of medical students' simulated experiences.
    Br J Dermatol. 2017 Feb 23. doi: 10.1111/bjd.15402.
    PubMed     Text format     Abstract available


  71. JORDAN M, Ghoreschi K
    Anti-melanoma differentiation-associated protein 5 autoantibodies as a marker for dermatomyositis-associated interstitial lung disease.
    Br J Dermatol. 2017;176:294-295.
    PubMed     Text format    


    January 2017
  72. WOLNER ZJ, Marghoob AA, Pulitzer MP, Postow MA, et al
    A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.
    Br J Dermatol. 2017 Jan 28. doi: 10.1111/bjd.15354.
    PubMed     Text format     Abstract available


  73. VANHAECKE C, Deilhes F, Chanal J, Regnier-Rosencher E, et al
    BRAFV600 inhibitor discontinuation after complete response in advanced melanoma. A retrospective analysis of 16 patients.
    Br J Dermatol. 2017 Jan 27. doi: 10.1111/bjd.15345.
    PubMed     Text format     Abstract available


  74. KUNTE C, Letule V, Gehl J, Dahlstroem K, et al
    Electrochemotherapy in the treatment of metastatic malignant melanoma: A prospective cohort study by InspECT.
    Br J Dermatol. 2017 Jan 24. doi: 10.1111/bjd.15340.
    PubMed     Text format     Abstract available


  75. MINAGAWA A, Omodaka T, Koga H, Yokokawa Y, et al
    Nail apparatus melanoma thickness is associated with side and age.
    Br J Dermatol. 2017 Jan 24. doi: 10.1111/bjd.15318.
    PubMed     Text format     Abstract available


  76. KINSLER VA, O'Hare P, Bulstrode N, Calonje JE, et al
    Melanoma in congenital melanocytic naevi.
    Br J Dermatol. 2017 Jan 12. doi: 10.1111/bjd.15301.
    PubMed     Text format     Abstract available


    December 2016
  77. NEITTAANMAKI N, Salmivuori M, Polonen I, Jeskanen L, et al
    Hyperspectral imaging in detecting dermal invasion in lentigo maligna melanoma.
    Br J Dermatol. 2016 Dec 23. doi: 10.1111/bjd.15267.
    PubMed     Text format     Abstract available


  78. USHER-SMITH JA, Kassianos AP, Emery JD, Abel GA, et al
    Identifying people at higher risk of melanoma across the U.K.: a primary-care-based electronic survey.
    Br J Dermatol. 2016 Dec 23. doi: 10.1111/bjd.15181.
    PubMed     Text format     Abstract available


  79. HERMS F, Franck N, Kramkimel N, Fichel F, et al
    Neutrophilic eccrine hidradenitis in 2 patients treated with BRAF inhibitors: a new cutaneous adverse event.
    Br J Dermatol. 2016 Dec 22. doi: 10.1111/bjd.15259.
    PubMed     Text format     Abstract available


  80. RICHTIG G, Richtig E, Kashofer K, Koch L, et al
    Testing and clinical implications for non-V600 BRAF mutations in metastatic NRASmt melanoma.
    Br J Dermatol. 2016 Dec 7. doi: 10.1111/bjd.15222.
    PubMed     Text format     Abstract available


  81. LINOS E, Li WQ, Han J, Li T, et al
    Lifetime UV exposure and Lentigo Maligna Melanoma.
    Br J Dermatol. 2016 Dec 7. doi: 10.1111/bjd.15218.
    PubMed     Text format     Abstract available


  82. SPENDER LC, Inman GJ
    Fatal attractions? Correlations of CXCL12-CXCR4-CXCR7 expression with disease progression in melanoma and Kaposi sarcoma.
    Br J Dermatol. 2016;175:1140-1141.
    PubMed     Text format    


  83. YELAMOS O, Nehal KS
    Integrating clinical information, dermoscopy and reflectance confocal microscopy to improve the diagnostic accuracy and confidence of amelanotic and lightly pigmented melanomas.
    Br J Dermatol. 2016;175:1147-1148.
    PubMed     Text format    


  84. HAASS NK
    JNK-ERK signalling in melanoma: rewired or entangled?
    Br J Dermatol. 2016;175:1139-1140.
    PubMed     Text format    


  85. DIXON A, Steinman H, Anderson S, Nirenberg A, et al
    Routine usage of sentinel node biopsy in melanoma management must cease.
    Br J Dermatol. 2016;175:1340-1341.
    PubMed     Text format    


    November 2016
  86. SPEIGL L, Janssen N, Weide B, Pawelec G, et al
    Prognostic impact of the putative cancer stem cell markers ABCG2, CD133, ALDH1A1 and CD44V7/8 in metastatic melanoma.
    Br J Dermatol. 2016 Nov 21. doi: 10.1111/bjd.15194.
    PubMed     Text format     Abstract available


  87. MAHER NG, Blumetti TP, Gomes EE, Cheng HM, et al
    Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions.
    Br J Dermatol. 2016 Nov 18. doi: 10.1111/bjd.15187.
    PubMed     Text format     Abstract available


  88. POLESIE S, Gillstedt M, Sonnergren HH, Osmancevic A, et al
    Methotrexate Treatment and Risk for Cutaneous Malignant Melanoma - a Retrospective Comparative Registry-based Cohort Study.
    Br J Dermatol. 2016 Nov 10. doi: 10.1111/bjd.15170.
    PubMed     Text format     Abstract available


  89. BARRETT JH
    Telomere length and melanoma - is there a straightforward relationship?
    Br J Dermatol. 2016;175:865-866.
    PubMed     Text format    


  90. ELLIKER KR, Williams HC
    Detection of skin cancer odours using dogs: a step forward in melanoma detection training and research methodologies.
    Br J Dermatol. 2016;175:851-852.
    PubMed     Text format    


  91. EISEMANN N
    Routine health data in skin cancer screening evaluation.
    Br J Dermatol. 2016;175:862.
    PubMed     Text format    


    October 2016
  92. RICHTIG G, Byrom L, Kupsa R, Schaider H, et al
    Pregnancy as driver for melanoma.
    Br J Dermatol. 2016 Oct 8. doi: 10.1111/bjd.15124.
    PubMed     Text format     Abstract available


  93. MAIQUES O, Macia A, Moreno S, Barcelo C, et al
    Immunohistochemical analysis of T-type calcium channels in acquired melanocytic nevi and melanoma.
    Br J Dermatol. 2016 Oct 8. doi: 10.1111/bjd.15121.
    PubMed     Text format     Abstract available


  94. O'SHEA SJ, Davies JR, Newton-Bishop JA
    Vitamin D, vitamin A, the primary melanoma transcriptome and survival.
    Br J Dermatol. 2016;175 Suppl 2:30-34.
    PubMed     Text format     Abstract available


    September 2016
  95. PIZZICHETTA MA, Kittler H, Stanganelli I, Ghigliotti G, et al
    Dermoscopic diagnosis of amelanotic/hypomelanotic melanoma.
    Br J Dermatol. 2016 Sep 28. doi: 10.1111/bjd.15093.
    PubMed     Text format     Abstract available


  96. WEINSTOCK MA, Lott JP, Wang Q, Titus LJ, et al
    Skin Biopsy Utilization and Melanoma Incidence among Medicare Beneficiaries.
    Br J Dermatol. 2016 Sep 17. doi: 10.1111/bjd.15077.
    PubMed     Text format     Abstract available


  97. LO MC, Maraka J, Garioch J, John WG, et al
    Monitoring vitamin D in the melanoma patient - impact of sun avoidance on vitamin D levels of melanoma patients at a tertiary UK referral melanoma service.
    Br J Dermatol. 2016 Sep 17. doi: 10.1111/bjd.15062.
    PubMed     Text format     Abstract available


  98. SCHUURMAN MS, de Waal AC, Thijs EJ, van Rossum MM, et al
    Risk factors for second primary melanoma among Dutch melanoma patients.
    Br J Dermatol. 2016 Sep 5. doi: 10.1111/bjd.15024.
    PubMed     Text format     Abstract available


  99. FOX J
    A changing treatment paradigm: the role of palliative care in metastatic melanoma.
    Br J Dermatol. 2016;175:462-3.
    PubMed     Text format    


    August 2016
  100. RIBERO S, Marra E, Tomasini CF, Fierro MT, et al
    Confocal microscopy and dermoscopy for the monitoring of BRAF inhibitor therapy of melanoma skin metastases.
    Br J Dermatol. 2016 Aug 12. doi: 10.1111/bjd.14951.
    PubMed     Text format     Abstract available


  101. RIBERO S, Osella-Abate S, Reyes-Garcia D, Grulich A, et al
    Gender effects on naevi body distribution and melanoma risk in two melanoma case control studies at different latitudes.
    Br J Dermatol. 2016 Aug 1. doi: 10.1111/bjd.14915.
    PubMed     Text format     Abstract available


    July 2016
  102. MANGAS C, Potrony M, Mainetti C, Bianchi E, et al
    Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
    Br J Dermatol. 2016 Jul 30. doi: 10.1111/bjd.14897.
    PubMed     Text format     Abstract available


  103. WILLIS CM, Britton LE, Swindells MA, Jones EM, et al
    Invasive melanoma in-vivo can be distinguished from basal cell carcinoma, benign naevi and healthy skin by canine olfaction: a proof of principle study of differential volatile organic compound emission.
    Br J Dermatol. 2016 Jul 25. doi: 10.1111/bjd.14887.
    PubMed     Text format     Abstract available


  104. GRANT WB
    Increased risk of non-cutaneous malignancy after diagnosis of non-melanoma skin cancer may be due to sun avoidance.
    Br J Dermatol. 2016 Jul 15. doi: 10.1111/bjd.14862.
    PubMed     Text format     Abstract available


  105. PARDO LM, van der Leest RJ, de Vries E, Soerjomataram I, et al
    Comparing survival of patients with single or multiple primary melanoma in The Netherlands: 1994-2009.
    Br J Dermatol. 2016 Jul 5. doi: 10.1111/bjd.14846.
    PubMed     Text format     Abstract available


  106. KIRBY LC, Banerjee A, Augustine T, Douglas JF, et al
    An ethical dilemma: malignant melanoma in a 51-year-old patient awaiting simultaneous kidney and pancreas transplantation for type 1 diabetes.
    Br J Dermatol. 2016;175:172-4.
    PubMed     Text format     Abstract available


    June 2016
  107. SHITARA D, Tell-Marti G, Badenas C, Enokihara MM, et al
    Discrepant mutational status between naevi and melanomas in naevus-associated melanomas: about mutation-specific immunohistochemistry: reply from the authors.
    Br J Dermatol. 2016 Jun 16. doi: 10.1111/bjd.14613.
    PubMed     Text format    


  108. TEULINGS HE, Lommerts JE, Wolkerstorfer A, Nieuweboer-Krobotova L, et al
    Vitiligo-like depigmentations as first sign of melanoma; a retrospective case series from a tertiary vitiligo centre.
    Br J Dermatol. 2016 Jun 7. doi: 10.1111/bjd.14790.
    PubMed     Text format     Abstract available


  109. WANG CC, Tang CH, Wang CY, Huang SY, et al
    Risk of skin cancer in chronic haemodialysis patients: a nationwide, population-based study in Taiwan.
    Br J Dermatol. 2016 Jun 7. doi: 10.1111/bjd.14789.
    PubMed     Text format     Abstract available


  110. STEFANAKI I, Stratigos AJ
    Inherited susceptibility to melanoma: insights from a high-risk Austrian cohort.
    Br J Dermatol. 2016;174:1188-90.
    PubMed     Text format    


    May 2016
  111. RANSOHOFF KJ, Stefanick ML, Li S, Kurian AW, et al
    Association of non-melanoma skin cancer with second non-cutaneous malignancy in the Women's Health Initiative.
    Br J Dermatol. 2016 May 26. doi: 10.1111/bjd.14766.
    PubMed     Text format     Abstract available


  112. TRAUTMANN F, Meier F, Seidler A, Schmitt J, et al
    Effects of the German skin cancer screening program on melanoma incidence and indicators of disease severity.
    Br J Dermatol. 2016 May 20. doi: 10.1111/bjd.14758.
    PubMed     Text format     Abstract available


  113. GUITERA P, Menzies SW, Argenziano G, Longo C, et al
    Dermoscopy and in vivo confocal microscopy are complimentary techniques for the diagnosis of difficult amelanotic and light colored skin lesions.
    Br J Dermatol. 2016 May 13. doi: 10.1111/bjd.14749.
    PubMed     Text format     Abstract available


  114. THURNEYSEN S, Cheng PF, Nagel HW, Kunz M, et al
    An exploratory study investigating the metabolic activity and local cytokine profile in melanoma patients treated with pazopanib and paclitaxel.
    Br J Dermatol. 2016 May 11. doi: 10.1111/bjd.14727.
    PubMed     Text format     Abstract available


  115. MCCONNELL AT, Ellis R, Pathy B, Plummer R, et al
    The prognostic significance and impact of the CXCR4/CXCR7/CXCL12 axis in primary cutaneous melanoma.
    Br J Dermatol. 2016 May 11. doi: 10.1111/bjd.14720.
    PubMed     Text format     Abstract available


  116. PATHRIA G, Garg B, Garg K, Wagner C, et al
    Dual JNK-Cyclin D1 and ERK-c-JUN Disjunction in Human Melanoma.
    Br J Dermatol. 2016 May 5. doi: 10.1111/bjd.14713.
    PubMed     Text format     Abstract available


  117. PIANA S, Moscarella E, Longo C
    Image Gallery: Brain? no, melanoma.
    Br J Dermatol. 2016;174:e41.
    PubMed     Text format    


  118. SCHOFIELD JK, Robinson R, Reeken S, Jackson R, et al
    National Institute for Health and Care Excellence melanoma guidelines: good news for patients but challenging to implement.
    Br J Dermatol. 2016;174:949-50.
    PubMed     Text format    


  119. LLOYD-LAVERY A, Hodgson T, Coupe N, Bond S, et al
    Delayed oral toxicity from long-term vemurafenib therapy.
    Br J Dermatol. 2016;174:1159-60.
    PubMed     Text format    


  120. LALLAS A, Tschandl P, Kyrgidis A, Stolz W, et al
    Dermoscopic clues to differentiate facial lentigo maligna from pigmented actinic keratosis.
    Br J Dermatol. 2016;174:1079-85.
    PubMed     Text format     Abstract available


  121. GREVELING K, de Vries K, van Doorn MB, Prens EP, et al
    A two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod: excellent cosmesis, but frequent recurrences on the nose.
    Br J Dermatol. 2016;174:1134-6.
    PubMed     Text format    


    April 2016
  122. MENIN C, Bojnik E, Del Bianco P, Elefanti L, et al
    Differences in telomere length between sporadic and familial cutaneous melanoma.
    Br J Dermatol. 2016 Apr 7. doi: 10.1111/bjd.14652.
    PubMed     Text format     Abstract available


  123. GALLAIS SEREZAL I, Beaussant Y, Rochigneux P, Tournigand C, et al
    End-of-life care for hospitalised patients with metastatic melanoma in France: a nationwide, register-based study.
    Br J Dermatol. 2016 Apr 1. doi: 10.1111/bjd.14631.
    PubMed     Text format     Abstract available


  124. HORSHAM C, J Loescher L, Whiteman DC, Soyer HP, et al
    Consumer acceptance of patient-performed mobile teledermoscopy for the early detection of melanoma.
    Br J Dermatol. 2016 Apr 1. doi: 10.1111/bjd.14630.
    PubMed     Text format     Abstract available


  125. OREGAARD JS, Jarjis RD, Venzo A, Jemec B, et al
    Cover Image: Unique presentation of a subungual malignant melanoma in situ.
    Br J Dermatol. 2016;174:935.
    PubMed     Text format    


  126. SULLIVAN RJ
    Serum lactate dehydrogenase is a more useful biomarker of prognosis than serum S100B in patients with BRAF-mutant melanoma.
    Br J Dermatol. 2016;174:716-7.
    PubMed     Text format    


  127. BAADE PD
    Quantifying the mortality burden for skin cancers other than melanoma.
    Br J Dermatol. 2016;174:713-4.
    PubMed     Text format    


  128. NILSEN LT, Hannevik M, Veierod MB
    Ultraviolet exposure from indoor tanning devices: a systematic review.
    Br J Dermatol. 2016;174:730-40.
    PubMed     Text format     Abstract available


    March 2016
  129. UGUEN A
    Discrepant mutational status between naevi and melanomas in naevus-associated melanomas: about mutation-specific immunohistochemistry.
    Br J Dermatol. 2016 Mar 31. doi: 10.1111/bjd.14603.
    PubMed     Text format     Abstract available


  130. PARKINS G, Brown E, Gupta G
    Radiological imaging in all stage III melanoma- current practice in the United Kingdom.
    Br J Dermatol. 2016 Mar 15. doi: 10.1111/bjd.14551.
    PubMed     Text format     Abstract available


  131. PARTARRIEU-MEJIAS F, Perez-Velasquez F
    Image Gallery: Xeroderma pigmentosum.
    Br J Dermatol. 2016;174:e12.
    PubMed     Text format    


  132. DE VRIES K, Greveling K, Prens LM, Munte K, et al
    Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision.
    Br J Dermatol. 2016;174:588-93.
    PubMed     Text format     Abstract available


  133. BELLON T, Lerma V, Gonzalez-Valle O, Gonzalez Herrada C, et al
    Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.
    Br J Dermatol. 2016;174:621-4.
    PubMed     Text format     Abstract available


    February 2016
  134. CHAPPUIS P, Duru G, Marchal O, Girier P, et al
    Dermoscopy: A useful tool for general practitioners in melanoma screening: A nationwide survey.
    Br J Dermatol. 2016 Feb 23. doi: 10.1111/bjd.14495.
    PubMed     Text format     Abstract available


  135. STASER K, Chen D, Solus J, Rosman IS, et al
    Extensive tumoral melanosis associated with ipilimumab-treated melanoma.
    Br J Dermatol. 2016 Feb 15. doi: 10.1111/bjd.14474.
    PubMed     Text format     Abstract available


  136. SARGEN MR, Merrill SL, Chu EY, Nathanson KL, et al
    CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic nevi, and internal malignancies: A case series and review of the literature.
    Br J Dermatol. 2016 Feb 15. doi: 10.1111/bjd.14485.
    PubMed     Text format     Abstract available


  137. NALDI L, Cazzaniga S
    Prediction of high total naevus count to estimate melanoma risk. We need more, don't we?
    Br J Dermatol. 2016;174:261-2.
    PubMed     Text format    


  138. LEE S, Duffy DL, McClenahan P, Lee KJ, et al
    Heritability of naevus patterns in an adult twin cohort from the Brisbane Twin Registry: a cross-sectional study.
    Br J Dermatol. 2016;174:356-63.
    PubMed     Text format     Abstract available


    January 2016
  139. MULLER C, Wendt J, Rauscher S, Burgstaller-Muehlbacher S, et al
    Characterization of high risk melanoma patients in Austria.
    Br J Dermatol. 2016 Jan 22. doi: 10.1111/bjd.14407.
    PubMed     Text format     Abstract available


  140. MATTER-WALSTRA K, Braun R, Kolb C, Ademi Z, et al
    Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors.
    Br J Dermatol. 2016 Jan 20. doi: 10.1111/bjd.14279.
    PubMed     Text format    


  141. CHMIELOWSKI B
    Prognostic and predictive biomarkers for the benefit of immunotherapy in patients with metastatic melanoma.
    Br J Dermatol. 2016;174:20.
    PubMed     Text format    


  142. CLIFF SH
    Five-year recurrence rate of lentigo maligna after off-label treatment with imiquimod.
    Br J Dermatol. 2016;174:22-3.
    PubMed     Text format    


  143. KAI AC, Richards T, Coleman A, Mallipeddi R, et al
    Five-year recurrence rate of lentigo maligna after treatment with imiquimod.
    Br J Dermatol. 2016;174:165-8.
    PubMed     Text format     Abstract available


    December 2015
  144. FERNANDEZ-VEGA I, Santos-Juanes J, Fresno-Forcelledo MF
    Primary amelanotic rhabdoid melanoma of the forehead.
    Br J Dermatol. 2015 Dec 29. doi: 10.1111/bjd.14382.
    PubMed     Text format     Abstract available


  145. ROACH RE, Plasmeijer EI, van Doorn R, Bergman W, et al
    The value of clinical characteristics for the diagnosis of melanoma in patients presenting at a pigmented lesion clinic.
    Br J Dermatol. 2015 Dec 26. doi: 10.1111/bjd.14375.
    PubMed     Text format     Abstract available


  146. EISEMANN N, Jansen L, Castro FA, Chen T, et al
    Survival from non-melanoma skin cancer in Germany.
    Br J Dermatol. 2015 Dec 16. doi: 10.1111/bjd.14352.
    PubMed     Text format     Abstract available


  147. FRAUCHIGER AL, Mangana J, Rechsteiner M, Moch H, et al
    Prognostic relevance of LDH and serum S-100 levels in Stage IV melanoma with known BRAF mutation status.
    Br J Dermatol. 2015 Dec 13. doi: 10.1111/bjd.14347.
    PubMed     Text format     Abstract available


  148. CURL PK
    Navigating uncertainty: a valuable cost-effectiveness analysis in the rapidly changing field of metastatic melanoma treatment.
    Br J Dermatol. 2015;173:1365-6.
    PubMed     Text format    


  149. MILLINGTON GW
    Growth and hormonal profiling in children with congenital melanocytic naevi.
    Br J Dermatol. 2015;173:1366-7.
    PubMed     Text format    


    November 2015
  150. TSCHANDL P, Berghoff AS, Preusser M, Pammer J, et al
    Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and nevi in vivo.
    Br J Dermatol. 2015 Nov 28. doi: 10.1111/bjd.14323.
    PubMed     Text format     Abstract available


  151. MONCRIEFF M, Fadhil M, Garrioch J
    Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases (LIMMs) of the skin. The 5-Year Norwich experience.
    Br J Dermatol. 2015 Nov 24. doi: 10.1111/bjd.14314.
    PubMed     Text format     Abstract available


  152. GUIDA S, Pellacani G, Cesinaro AM, Moscarella E, et al
    Spitz naevi and melanomas with similar dermoscopic pattern: can confocal microscopy differentiate?
    Br J Dermatol. 2015 Nov 11. doi: 10.1111/bjd.14286.
    PubMed     Text format     Abstract available


  153. SEBARATNAM DF, Anforth R, Fernandez-Penas P
    Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma.
    Br J Dermatol. 2015 Nov 2. doi: 10.1111/bjd.14264.
    PubMed     Text format     Abstract available


    October 2015
  154. RIBERO S, Zugna D, Osella-Abate S, Glass D, et al
    Prediction of high naevus count in a healthy UK population to estimate melanoma risk.
    Br J Dermatol. 2015 Oct 19. doi: 10.1111/bjd.14216.
    PubMed     Text format     Abstract available


    September 2015
  155. MOSER J, Moshammer R, Koglbauer G, Kitzwogerer M, et al
    Sentinel-node biopsy in melanoma: A single center experience with 216 consecutive patients.
    Br J Dermatol. 2015 Sep 24. doi: 10.1111/bjd.14189.
    PubMed     Text format     Abstract available


  156. ZARAGOZA J, Caille A, Beneton N, Bens G, et al
    Neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.
    Br J Dermatol. 2015 Sep 6. doi: 10.1111/bjd.14155.
    PubMed     Text format     Abstract available


  157. MATTER-WALSTRA K, Braun R, Kolb C, Ademi Z, et al
    A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-positive melanoma in the Swiss setting.
    Br J Dermatol. 2015 Sep 2. doi: 10.1111/bjd.14152.
    PubMed     Text format     Abstract available


  158. KRAFT S, Tsao H
    Melanoma-associated naevi: precursors or coincidence?
    Br J Dermatol. 2015;173:633-4.
    PubMed     Text format    


  159. SCHOFIELD JK
    Sentinel lymph node biopsy: in support of equity of access, informed shared decision making and patient choice.
    Br J Dermatol. 2015;173:863-4.
    PubMed     Text format    


    August 2015
  160. CHAVEZ-BOURGEOIS M, Iglesias P, Brito J, Malvehy J, et al
    Skin cancers detected as casual findings with Reflectance Confocal Microscopy (RCM) in the assessment of melasma treatment.
    Br J Dermatol. 2015 Aug 12. doi: 10.1111/bjd.14066.
    PubMed     Text format     Abstract available


  161. MONCRIEFF M, Garioch J
    MSLT-I: it's all about the lymph nodes....
    Br J Dermatol. 2015;173:626-7.
    PubMed     Text format    


  162. MCGREGOR JM, Sasieni P
    MSLT-I: it's all about the lymph nodes...: reply from the authors.
    Br J Dermatol. 2015;173:627-8.
    PubMed     Text format    


    July 2015
  163. BENATI E, Argenziano G, Kyrgidis A, Moscarella E, et al
    Melanoma and naevi with globular pattern: Confocal microscopy as an aid for diagnostic differentiation.
    Br J Dermatol. 2015 Jul 25. doi: 10.1111/bjd.14049.
    PubMed     Text format     Abstract available


  164. LALLAS A, Kyrgidis A, Koga H, Moscarella E, et al
    The BRAAFF checklist: a new dermoscopic algorithm for diagnosing acral melanoma.
    Br J Dermatol. 2015 Jul 25. doi: 10.1111/bjd.14045.
    PubMed     Text format     Abstract available


  165. LI Z, Wang Z, Yu Y, Zhang H, et al
    Smoking is Inversely Related to Cutaneous Malignant Melanoma -Says Results from a Meta-analysis.
    Br J Dermatol. 2015 Jul 2. doi: 10.1111/bjd.13998.
    PubMed     Text format     Abstract available


  166. DAVIES MA
    BRAF in early stage melanoma: rationale for testing and treatment?
    Br J Dermatol. 2015;173:9-10.
    PubMed     Text format    


  167. GOHARA M
    Skin cancer: an African perspective.
    Br J Dermatol. 2015;173 Suppl 2:17-21.
    PubMed     Text format     Abstract available


    June 2015
  168. SINHA R, Larkin J, Gore M, Fearfield L, et al
    Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Br J Dermatol. 2015 Jun 24. doi: 10.1111/bjd.13958.
    PubMed     Text format     Abstract available


  169. BENATI E, Zalaudek I, Piana S, Argenziano G, et al
    In vivo detection of peripheral clefting in melanocytic lesions.
    Br J Dermatol. 2015 Jun 23. doi: 10.1111/bjd.13959.
    PubMed     Text format     Abstract available


  170. FINNANE A, Soyer HP
    Smartphone diagnosis of skin cancer: there's not yet an app for that.
    Br J Dermatol. 2015;172:1474-5.
    PubMed     Text format    


  171. WU S
    Do mutations in BRCA1/BRCA2 confer a higher risk of skin cancer?
    Br J Dermatol. 2015;172:1473.
    PubMed     Text format    


  172. GUMASTE PV, Penn LA, Cymerman RM, Kirchhoff T, et al
    Skin cancer risk in BRCA1/2 mutation carriers.
    Br J Dermatol. 2015;172:1498-506.
    PubMed     Text format     Abstract available


  173. VIGARIOS E, Lamant L, Delord JP, Fricain JC, et al
    Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.
    Br J Dermatol. 2015;172:1680-2.
    PubMed     Text format    


    May 2015
  174. THOMAS L
    Dermoscopy for melanoma: don't forget to take a photo.
    Br J Dermatol. 2015;172:1182-3.
    PubMed     Text format    


    April 2015
  175. OAKLEY AM
    Mobile teledermatology is here to stay.
    Br J Dermatol. 2015;172:856-7.
    PubMed     Text format    


  176. MANAHAN MN, Soyer HP, Loescher LJ, Horsham C, et al
    A pilot trial of mobile, patient-performed teledermoscopy.
    Br J Dermatol. 2015;172:1072-80.
    PubMed     Text format     Abstract available


  177. DEBARBIEUX S, Gaspar R, Depaepe L, Dalle S, et al
    Intraoperative diagnosis of nonpigmented nail tumours with ex vivo fluorescence confocal microscopy: 10 cases.
    Br J Dermatol. 2015;172:1037-44.
    PubMed     Text format     Abstract available


    January 2015
  178. LONGO C, Moscarella E, Argenziano G, Lallas A, et al
    Reflectance confocal microscopy in the diagnosis of solitary pink skin tumors: Review of Diagnostic Clues.
    Br J Dermatol. 2015 Jan 30. doi: 10.1111/bjd.13689.
    PubMed     Text format     Abstract available


  179. JEUDY G, Dalac-Rat S, Bonniaud B, Hervieu A, et al
    Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.
    Br J Dermatol. 2015;172:1454-5.
    PubMed     Text format    


  180. RICHTIG E, Arzberger E, Hofmann-Wellenhof R, Fink-Puches R, et al
    Assessment of changes in lentigo maligna during radiotherapy by in-vivo reflectance confocal microscopy: a pilot study.
    Br J Dermatol. 2015;172:81-7.
    PubMed     Text format     Abstract available


    August 2014
  181. MOSCARELLA E, Al Jalbout S, Piana S, Argenziano G, et al
    The stars within the melanocytic garden: Unusual variants of Spitz nevi.
    Br J Dermatol. 2014 Aug 13. doi: 10.1111/bjd.13347.
    PubMed     Text format     Abstract available


  182. LAWRENCE CM, Rahim R, Charlton F, Husain A, et al
    Prospective study of formalin-fixed Mohs surgery and haematoxylin and eosin stains with control contralateral biopsies for lentigo maligna: 5-year follow-up results.
    Br J Dermatol. 2014;171:298-303.
    PubMed     Text format     Abstract available


    July 2014
  183. BRUGIERE C, Stefan A, Morice C, Cornet E, et al
    Vemurafenib skin phototoxicity is indirectly linked to UVA-MED decrease.
    Br J Dermatol. 2014 Jul 26. doi: 10.1111/bjd.13300.
    PubMed     Text format     Abstract available


    May 2014
  184. PELLACANI G, Pepe P, Casari A, Longo C, et al
    Reflectance confocal microscopy as a second-level examination in skin oncology improves diagnostic accuracy and saves unnecessary excisions: a longitudinal prospective study.
    Br J Dermatol. 2014 May 29. doi: 10.1111/bjd.13148.
    PubMed     Text format     Abstract available


    April 2014
  185. KOSE K, Cordova M, Duffy M, Flores ES, et al
    Video-Mosaicing of Reflectance Confocal Images For Examination of Extended Areas of Skin In Vivo.
    Br J Dermatol. 2014 Apr 10. doi: 10.1111/bjd.13050.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: